What is iGenetic Diagnostics?
Headquartered in Mumbai, iGenetic Diagnostics operates as a next-generation diagnostic powerhouse, offering a comprehensive menu of over 1,400 investigations. The company distinguishes itself through an accredited central laboratory model supported by a widespread network of collection centers. Its core competency lies in the integration of specialized cytogenetic and molecular testing, which are essential for modern clinical decision-making in oncology and gynaecology. By prioritizing the introduction of advanced medical technologies, iGenetic Diagnostics is actively reshaping the standard of care for the Indian population, ensuring that high-end pathological investigations are both accurate and clinically actionable.
How much funding has iGenetic Diagnostics raised?
iGenetic Diagnostics has raised a total of $20.5M across 2 funding rounds:
Angel/Seed
$1M
Private Equity
$19.5M
Angel/Seed (2016): $1M, investors not publicly disclosed
Private Equity (2017): $19.5M led by CDC Group Plc and Manipal Education and Medical Group
Key Investors in iGenetic Diagnostics
CDC Group Plc
A development finance institution with a focus on supporting sustainable growth and infrastructure development in emerging markets.
Manipal Education and Medical Group
A diversified conglomerate operating across education, healthcare, and research, committed to providing socially relevant and affordable services.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for iGenetic Diagnostics?
With the recent strategic investment, iGenetic Diagnostics is well-positioned to accelerate its technological roadmap and expand its footprint within the competitive Indian healthcare market. The focus will likely shift toward enhancing its digital diagnostic capabilities and deepening its penetration into tier-two and tier-three cities, where the demand for specialized molecular diagnostics is rising. Furthermore, the company is expected to leverage its existing research and development framework to introduce novel diagnostic markers, thereby maintaining its competitive edge in the rapidly evolving landscape of personalized medicine and critical care diagnostics.
See full iGenetic Diagnostics company page
